Sign In
Buy NRSN
$0.465
-0.0108 (-2.27%)
At Close: Jul 31, 2026
NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price
08:49am, Thursday, 04'th Sep 2025
Financing at 40% premium to market price provides near-term bridge to anticipated milestones CAMBRIDGE, Mass. , Sept. 4, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Provides Business Update and Progress for the First Half of 2025
09:00am, Friday, 01'st Aug 2025
CAMBRIDGE, Mass. , July 31, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Live Broadcast: Award-Winning Actor & ALS Advocate Aaron Lazar hosts NeuroSense CEO Alon Ben-Noon to Unveil New Insights into NeuroSense's Breakthrough Science, Canadian Regulatory Milestones & Go-to-
Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights
03:08pm, Monday, 12'th May 2025
Last Wednesday, NeuroSense Therapeutics Ltd. NRSN said it scaled up its production of PrimeC to a commercial scale.
NeuroSense Announces Global CDMO Selection and Manufacturing Scale-Up, Enabling Rapid Pathway to Commercialization for What is Projected to be a $100-150M Canadian Market Opportunity CAMBRIDGE, Mass.
NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update
09:09am, Thursday, 24'th Apr 2025
Letter outlines Phase 3 timeline for PrimeC in ALS, provides update on Canadian regulatory pathway and strategic partnership discussions; Company optimistic about ongoing partnership discussions with
NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment
08:30am, Wednesday, 09'th Apr 2025
New miRNA findings unveiled at the AAN, reveal key biological mechanisms behind PrimeC's clinical benefit in ALS. CAMBRIDGE, Mass.
NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates
05:14pm, Monday, 07'th Apr 2025
Phase 2b study completed in amyotrophic lateral sclerosis (ALS) demonstrated lead asset PrimeC slows disease progression and functional decline Ongoing partnership discussions to advance PrimeC to Pha
Two presentations in the General Neurology and Late Breaker sessions will respectively cover new clinical and microRNA data from NeuroSense CAMBRIDGE, Mass. , April 4, 2025 /PRNewswire/ -- NeuroSense
Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug
10:30am, Thursday, 20'th Mar 2025
NEW YORK--(BUSINESS WIRE)--Market News Alerts Reports: NeuroSense Therapeutics Ltd. (NASDAQ: NRSN)* has announced significant progress toward the early commercialization of PrimeC in Canada. According
NEW YORK--(BUSINESS WIRE)---- $NRSN #ALS--PESG Research releases a new report covering NeuroSense Therapeutics (NASDAQ: NRSN)* and its recent developments: In a medical landscape hungry for innovation
NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement
09:00am, Monday, 06'th Jan 2025
NeuroSense in Compliance with all Nasdaq Listing Requirements CAMBRIDGE, Mass. , Jan. 6, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS
09:00am, Monday, 23'rd Dec 2024
Binding Term Sheet with a leading global pharmaceutical company includes a substantial upfront payment and funding for the Phase 3 study Additionally, milestone payments and double-digit royalties on
NeuroSense Provides Business Update and Third Quarter 2024 Financial Results
10:25am, Wednesday, 18'th Dec 2024
CAMBRIDGE, Mass. , Dec. 18, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC
09:25am, Wednesday, 11'th Dec 2024
The Type C meeting with the FDA, combined with the recent 18-month Phase 2b PARADIGM study readout, has the Company on track to commence a Phase 3 study in mid-2025 PrimeC has already demonstrated a s
